Agomab Therapeutics NV
NASDAQ · AGMB·Antwerp, Belgium·Small-cap·Phase 2
Belgian clinical-stage biopharma (Feb 2026 Nasdaq IPO) developing disease-modifying therapies for fibrotic and inflammatory diseases. Lead asset ontunisertib (AGMB-129) is a gut-restricted oral ALK5/TGFβR1 inhibitor in Phase 2a for fibrostenosing Crohn's disease, with a second tissue-restricted ALK5 inhibitor (AGMB-447, inhaled, IPF) in Phase 1.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Agomab Investor Presentation | Corporate overview | March 4, 2026 | 50 |